Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 272

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 272
---
 this offering, our audit committee will consist of Rekha Hemrajani, Robert R. Ruffolo, Jr., and Scott Garland, with Ms. Hemrajani serving as the chair of the audit committee. Our board of directors has determined that each of these
individuals satisfies the requirements for independence under the current rules and regulations of the SEC and the listing standards of Nasdaq. Each member of our audit committee can read and understand fundamental financial statements in accordance
with Nasdaq audit committee requirements. In addition, our board of directors has determined that Ms. Hemrajani and Mr. Garland each qualifies as an “audit committee financial expert” within the meaning of SEC regulations. In arriving at
these determinations, the board has examined each audit committee member’s scope of experience and the nature of their prior and/or current employment.

184

The primary responsibilities of the audit committee will include, among other things:

| • |     | helping our board of directors oversee our corporate accounting and financial reporting processes; |

| • |     | managing the selection, engagement, qualifications, independence, and performance of a qualified firm to serve as 
 the independent registered public accounting firm to audit our financial statements;                              |

| • |     | discussing the scope and results of the audit with the independent registered public accounting firm, and 
 reviewing, with management and the independent accountants, our interim and year-end operating results;   |

| • |     | developing procedures for employees to submit concerns anonymously about questionable accounting or audit 
 matters;                                                                                                  |

| • |     | reviewing related person transactions; |

| • |     | overseeing cybersecurity matters and policies; |

| • |     | obtaining and reviewing a report by the independent registered public accounting firm that describes its internal                                       
 quality control procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and |

| • |     | approving, or, as permitted, pre-approving, audit and permissible non-audit services to be performed by the independent registered public accounting firm. |

The audit committee will operate under a written charter, to be effective immediately prior to the closing of this offering, which satisfies the applicable rules and regulations of the SEC and the listing standards of Nasdaq. Compensation Committee Upon completion of this offering, our compensation committee will consist of Scott Garland, William Kane, and Rekha Hemrajani, with Mr. Garland serving as chair of the compensation committee. Our board of directors has determined that each of the members